Which of the following drug classes was not described as a migraine preventive option in the material?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which of the following drug classes was not described as a migraine preventive option in the material?

Monoclonal CGRP antibodies are a newer preventive option that specifically target CGRP signaling, usually given by monthly or quarterly injections. If the material you studied focused on older, established preventive categories and on oral agents like gepants, it may not have included these injectable monoclonal antibodies. That’s why this drug class stands out as the one not described. In the material, antidepressants and antihypertensive agents have long been used for migraine prevention, and oral CGRP antagonists (gepants) have been described as another preventive option. The monoclonal CGRP antibody class, though effective for prevention, wasn’t covered in that particular material, making it the option not described.

Monoclonal CGRP antibodies are a newer preventive option that specifically target CGRP signaling, usually given by monthly or quarterly injections. If the material you studied focused on older, established preventive categories and on oral agents like gepants, it may not have included these injectable monoclonal antibodies. That’s why this drug class stands out as the one not described.

In the material, antidepressants and antihypertensive agents have long been used for migraine prevention, and oral CGRP antagonists (gepants) have been described as another preventive option. The monoclonal CGRP antibody class, though effective for prevention, wasn’t covered in that particular material, making it the option not described.

More practice questions